fda and glp 1 warns about unapproved GLP-1 drugs online, calls for accessible trials | Medical Research Network posted on the topic FDA Offers Clarification on Compounded

There is a relative lack of prospective or randomised clinical studies in cohorts of PDM on specific interventions, such as advanced strategies to optimise enzyme replacement therapy, emerging insulin delivery systems or dual incretin agonists

Given the steep costs and high demand for these drugs, employers and insurers may continue to impose more restrictive eligibility standards for coverage than the clinical indications set by the Food and Drug Administration

These are real changes in brain chemistry

Qian F, Mathias N, Moench P, Chi C, Desikan S, Hussain M, et al

Document the incident, including the date and time